<i>PIK3CA</i> amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma

Hyo Song Kim(Yonsei University), Byoung Chul Cho(Yonsei University), Hyunki Kim(Yonsei University), Susan Jewell(Medisch Centrum Alkmaar), Young Mog Shim(Samsung Medical Center), Hye Ryun Kim(Yonsei University), Jin Hur(Yonsei University), Sung Kwan Shin(Yonsei University), Yong Chan Lee(Jeonbuk National University), Chang Geol Lee(Yonsei University), Hyunsoo Chung(Yonsei University), Seung Eun Lee(Samsung Medical Center), Yoon‐La Choi(Samsung Medical Center), Dae Joon Kim(Yonsei University), Jun Chul Park(Yonsei University), Yoon Sung Bae(Yonsei University), Sang Kil Lee(Yonsei University)
Oncotarget
April 15, 2016
10.18632/oncotarget.8749
Cited by 21

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
|Nature Medicine|2015|1.5k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537